Centre for the AIDS Programme of Research in South Africa (original) (raw)

In 2017, a landmark pricing agreement made generic dolutegravir accessible for HIV treatment in low-income and middle-income countries, costing approximately $75 annually for a fixed-dose combination. Dolutegravir, recognized for its superior efficacy and tolerability compared to existing treatments, is poised to enhance HIV care, especially where drug resistance is prevalent. However, key concerns regarding its safety during pregnancy, interactions with tuberculosis treatments, and implications for drug resistance remain critical issues that must be addressed as countries begin implementing dolutegravir-based regimens.